Stock Ratings / Health Care / CGEN / options

DTIL (24) ARTV (39) PALI (43) IVVD (30) ⌘ Pro Terminal →

Compugen Ltd. (CGEN) Options Positioning, Max Pain & Unusual Sweeps

$1.98 -2.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.97

Compugen Ltd. (CGEN) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (87% profit margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate) →

ROARABLE B+ • BUY Cap $193.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CGEN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Compugen Ltd. (NASDAQ: CGEN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1.98 (-2.94% 1D, market cap $193.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, CGEN ranks #23 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CGEN compare to DTIL and ARTV in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEN carries a Roarable B+ (78/100 RQD), trailing P/E of 5.5x, gross margin of 87.3%, and ROIC of 85.0%. By comparison, DTIL (Precision BioSciences Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M) and ARTV (Artiva Biotherapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CGEN?

▼

Per CGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001119774), Compugen Ltd. generated $72.8M in revenue (+161.1% YoY), $35.3M in net income, and $31.3M in free cash flow against $156.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.97 (-0.29%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 43.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+9.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGEN)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (78/100 Composite)

🔍 WHY CGEN SCORES 78/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+18/20 pts (23% of score)

FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 41.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$2.13-8% Next Q

Q2 (-2Q)

Grade A$1.96-1% Next Q

Q3 (-1Q)

Grade A-$1.94+2.1% Next Q

Current

Grade B+$1.98+7.9% Hist 90D α

Trajectory: A (86) → B+ (78)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CGEN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 78/100 (B+) score, CGEN faces multiple-compression risk if 5.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 84.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.32) or 200D SMA ($2.30) invalidates the momentum regime and cuts Target Base ($2.16) toward Bear Floor ($1.62).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 78%NO 22%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CGEN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CGEN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating CGEN & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on CGEN
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.56%▼ DESCENDING CHANNEL

2026-10-30O $2.02H $2.02L $1.92C $1.98VOL 255.4K

RES: $2.87SUP: $1.85SMA50: $2.32SMA200: $2.30

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGEN Butterfly Map → + Track CGEN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-12.3%/yr Implied 5Y Growth

vs. +161.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGEN)

Health Care Rank #23 of 1016 ⚔️ DTIL vs CGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGEN vs. DTIL, ARTV, PALI, IVVD)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Compugen Ltd. (CGEN) ranks #23 by composite RQD confidence (78/100, grade B+) and #581 by equity capitalization ($193.0M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CGEN ACTIVE Compugen Ltd.	B+	78/100	5.5x	87.3%	85.0%	-2.94%	$193.0M	Benchmark Subject
DTIL Precision BioSciences Inc.	E	24/100	—	—	-35.0%	-5.11%	$205.4M	/dtil-vs-cgen →
ARTV Artiva Biotherapeutics Inc.	D-	39/100	—	—	-35.0%	-0.95%	$206.8M	/artv-vs-cgen →
PALI Palisade Bio Inc.	D-	43/100	—	—	-35.0%	-2.52%	$207.4M	/pali-vs-cgen →
IVVD Invivyd Inc.	E	30/100	—	—	-35.0%	-3.37%	$177.4M	/ivvd-vs-cgen →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001119774

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Compugen Ltd. (CGEN) reported GAAP revenue of $72.8M (+161.1% vs. FY2024 revenue of $27.9M , and +117.5% cumulative change since FY2023) , GAAP net income of $35.3M, operating cash flow of $31.6M, and free cash flow of $31.3M (-36.7% YoY). On the balance sheet, CGEN closed FY2025 with $156.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$72.8M	$35.3M	$31.6M	$31.3M	$156.6M	—
FY2024 (FY)	2024-12-31	$27.9M	-$14.2M	$49.6M	$49.5M	$115.0M	—
FY2023 (FY)	2023-12-31	$33.5M	-$18.8M	-$35.9M	-$35.9M	—	—

3. CGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CGEN compare to DTIL and ARTV in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CGEN?

Where is CGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

CGEN last traded at $1.98 (-2.94% on volume of 255,462 shares), positioning the stock -14.66% below its 50-day simple moving average ($2.32) and -13.91% below its 200-day simple moving average ($2.30). Across its 52-week range of $1.43 to $3.24, CGEN sits at the 30.4% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.76 to $2.20).